Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease

被引:14
作者
Helmer, Catherine
Andrieu, Sandrine
Peres, Karine
Orgogozo, Jean-Marc
Vellas, Bruno
Dartigues, Jean-Francois
机构
[1] Univ Bordeaux 2, INSERM, U593, FR-33076 Bordeaux, France
[2] CHU Bordeaux, Federat Neurol, Bordeaux, France
[3] INSERM, U558, Toulouse, France
[4] CHU, Toulouse, France
关键词
ADAS-cog score; predictive value; Alzheimer's disease;
D O I
10.1159/000098516
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background/Aims: To determine the predictive value of the 6-month evolution of the ADAS-cog score in initially mild to moderate Alzheimer's disease (AD) patients on the risk of death or severe dementia (MMSE < 10) within 2 years. Methods: Cognition was assessed every 6 months using the ADAS-cog scale in the Real. fr study, a cohort of AD patients. Six classes of ADAS-cog evolution were distinguished, from the severest deterioration ( decline 6 7 points) to the greatest cognitive improvement ( gain 6 4 points). Results: Among 536 AD patients, 53 (9.9%) had a 6-month decline of 7 points or more. This group with the severest deterioration was significantly associated with the risk of severe dementia or death at 2 years ( relative risk, RR = 3.8, 95% confidence interval, Cl = 2.1-6.8), even after adjustment for baseline MMSE, disability and ADAS-cog score ( RR = 2.6, 95% CI = 1.4-5.0). In addition, subjects with a decline by at least 4 points were also at greater risk of severe dementia. Conclusion: These results confirm the value of the ADAS-cog scale as a judgement criterion in clinical trials since it is a good surrogate marker of long-term prognosis. The proportion of fast decliners on the ADAS-cog could be a helpful judgement criterion for future trials in AD. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 22 条
  • [1] Cholinesterase inhibitors for Alzheimer's disease
    Birks, J
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
  • [2] Commenges D, 1998, STAT MED, V17, P1973, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1973::AID-SIM892>3.0.CO
  • [3] 2-5
  • [4] European Medicine Evaluation Agency (EMEA), 1997, NOT GUID MED PROD TR
  • [5] The staging and assessment of moderate to severe Alzheimer disease
    Feldman, HH
    Woodward, M
    [J]. NEUROLOGY, 2005, 65 (06) : S10 - S17
  • [6] MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN
    FOLSTEIN, MF
    FOLSTEIN, SE
    MCHUGH, PR
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) : 189 - 198
  • [7] *FOOD DRUG COSM RE, 1992, FDA GUID ALZ DRUG DI, P13
  • [8] Gillette-Guyonnet S, 2003, J Nutr Health Aging, V7, P91
  • [9] Donepezil for severe Alzheimers disease
    Hogan, DB
    [J]. LANCET, 2006, 367 (9516) : 1031 - 1032
  • [10] Rate of cognitive decline and mortality in Alzheimer's disease
    Hui, JS
    Wilson, RS
    Bennett, DA
    Bienias, JL
    Gilley, DW
    Evans, DA
    [J]. NEUROLOGY, 2003, 61 (10) : 1356 - 1361